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D
iabetes is deﬁned by its association
with hyperglycemia-speciﬁc micro-
vascular complications; however, it
also imparts a two- to fourfold risk of car-
diovascular disease (CVD). Although mi-
crovascular complications can lead to
signiﬁcantmorbidityandprematuremor-
tality, by far the greatest cause of death in
people with diabetes is CVD.
Results from randomized controlled
trials have demonstrated conclusively
that the risk of microvascular complica-
tions can be reduced by intensive glyce-
mic control in patients with type 1 (1,2)
and type 2 diabetes (3–5). In the Diabe-
tes Control and Complications Trial
(DCCT),therewasan60%reductionin
development or progression of diabetic
retinopathy, nephropathy, and neuropa-
thy between the intensively treated group
(goal A1C 6.05%, mean achieved A1C
7%) and the standard group (A1C
9%) over an average of 6.5 years. The
relationship between glucose control (as
reﬂected by the mean on-study A1C
value) and risk of complications was log-
linear and extended down to the normal
A1C range (6%) with no threshold
noted.
In the UK Prospective Diabetes Study
(UKPDS), participants newly diagnosed
with type 2 diabetes were followed for 10
years, and intensive control (median A1C
7.0%)wasfoundtoreducetheoverallmi-
crovascular complication rate by 25%
compared with conventional treatment
(median A1C 7.9%). Here, too, second-
ary analyses showed a continuous relation-
ship between the risk of microvascular
complications and glycemia extending into
the normal range of A1C, with no glycemic
threshold.
On the basis of these two large con-
trolled trials, along with smaller studies
and numerous epidemiologic reports, the
consistentﬁndingsrelatedtomicrovascu-
lar risk reduction with intensive glycemic
control have led the American Diabetes
Association(ADA)torecommendanA1C
goalof7%formostadultswithdiabetes
(6), recognizing that more or less strin-
gent goals may be appropriate for certain
patients. Whereas many epidemiologic
studies and meta-analyses (7,8) have
clearly shown a direct relationship be-
tween A1C and CVD, the potential of in-
tensive glycemic control to reduce CVD
eventshasbeenlessclearlydeﬁned.Inthe
DCCT, there was a trend toward lower
risk of CVD events with intensive control
(risk reduction 41% [95% CI 10–68]),
butthenumberofeventswassmall.How-
ever, 9-year post-DCCT follow-up of the
cohort has shown that participants previ-
ously randomized to the intensive arm
had a 42% reduction (P  0.02) in CVD
outcomes and a 57% reduction (P 
0.02) in the risk of nonfatal myocardial
infarction (MI), stroke, or CVD death
compared with those previously in the
standard arm (9).
The UKPDS of type 2 diabetes ob-
served a 16% reduction in cardiovascular
complications(combinedfatalornonfatal
MI and sudden death) in the intensive
glycemic control arm, although this dif-
ference was not statistically signiﬁcant
(P  0.052), and there was no suggestion
ofbeneﬁtonotherCVDoutcomessuchas
stroke. However, in an epidemiologic
analysis of the study cohort, a continuous
associationwasobservedsuchthatforev-
ery percentage point of lower median on-
study A1C (e.g., 8–7%) there was a
statistically signiﬁcant 18% reduction in
CVD events, again with no glycemic
threshold.
Because of ongoing uncertainty re-
garding whether intensive glycemic con-
trol can reduce the increased risk of CVD
in people with type 2 diabetes, several
large long-term trials were launched in
the past decade to compare the effects of
intensive versus standard glycemic con-
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risk participants with established type 2
diabetes. In 2008, two of these trials, Ac-
tion in Diabetes and Vascular Disease—
Preterax and Diamicron Modiﬁed Release
Controlled Evaluation (ADVANCE) and
the Veterans Affairs Diabetes Trial
(VADT), were completed and showed no
signiﬁcant reduction in cardiovascular
outcomes with intensive glycemic con-
trol. A third trial, Action to Control Car-
diovascular Risk in Diabetes (ACCORD),
terminated its glycemic control study
early due to the ﬁnding of increased mor-
tality in participants randomized to a
strategyofveryintensiveglycemiccontrol
withatargetA1Cof6%.Theﬁndingsof
these three major trials led the ADA, with
representatives of the American Heart As-
sociation (AHA) and the American Col-
lege of Cardiology (ACC), to reexamine
therecommendationsforglycemictargets
in patients with diabetes, the majority of
whom have type 2 diabetes.
What did the ACCORD,
ADVANCE, and VA
Diabetes trials show?— Table
1 provides a summary of baseline charac-
teristics, glycemic treatment strategies
Table 1—Comparison of the three trials of intensive glycemic control and CVD outcomes
ACCORD ADVANCE VADT
Participant characteristics
n 10,251 11,140 1,791
Mean age (years) 62 66 60
Duration of diabetes (years) 10 8 11.5
Sex (% male/female) 39/61 42/58 97/3
History of CVD (%) 35 32 40
BMI (kg/m
2) 32 28 31
Median baseline A1C (%) 8.1 7.2 9.4
On insulin at baseline (%) 35 1.5 52
Protocol characteristics
A1C goals (%) (I vs. S)* 6.0 vs. 7.0–7.9 6.5 vs. “based on local
guidelines”
6.0 (action if 6.5) vs.
planned separation of 1.5
Protocol for glycemic control (I vs. S)* Multiple drugs in both
arms
Multiple drugs added to gliclizide
vs. multiple drugs with no
gliclizide
Multiple drugs in both arms
Management of other risk factors Embedded blood pressure
and lipid trials
Embedded blood pressure trial Protocol for intensive
treatment in both arms
On-study characteristics
Median duration of follow-up (years) 3.5 (terminated early) 5 5.6
Achieved median A1C (%) (I vs. S)* 6.4 vs. 7.5 6.3 vs. 7.0 6.9 vs. 8.5
On insulin at study end (%) (I vs. S)* 77 vs. 55* 40 vs. 24 89 vs. 74
On TZD at study end (%) (I vs. S)* 91 vs. 58* 17 vs. 11 53 vs. 42
On statin at study end (%) (I vs. S)* 88 vs. 88* 46 vs. 48 85 vs. 83
On aspirin at study end (%) (I vs. S)* 76 vs. 76* 57 vs. 55 88 vs. 86
Smokers at study end (%) 10 8 8
Mean blood pressure at study end
(mmHg)
Intensive glycemic control arm 126/67 136/74 127/68
Standard glycemic control arm 127/68 138/74 125/69
Weight changes (kg)
Intensive glycemic control arm 3.5 0.1 7.8
Standard glycemic control arm 0.4 1.0 3.4
Severe hypoglycemia (participants
with one or more episodes
during study) (%)
Intensive glycemic control arm 16.2 2.7 21.2
Standard glycemic control arm 5.1 1.5 9.9
Outcomes
Deﬁnition of primary outcome Nonfatal MI, nonfatal
stroke, CVD death
Microvascular plus macrovascular
(nonfatal MI, nonfatal stroke,
CVD death) outcomes
Nonfatal MI, nonfatal stroke,
CVD death,
hospitalization for heart
failure, revascularization
HR for primary outcome (95% CI) 0.90 (0.78–1.04) 0.9 (0.82–0.98); macrovascular
0.94 (0.84–1.06)
0.88 (0.74–1.05)
HR for mortality ﬁndings (95% CI) 1.22 (1.01–1.46) 0.93 (0.83–1.06) 1.07 (0.81–1.42)
*Medication rates for ACCORD are for any use during the study. I, intensive glycemic control; S, standard glycemic control; TZD, thiazolidinedione.
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trol, achieved glycemic control, and pri-
mary results of each of the three studies.
The ACCORD study randomized 10,251
participants with either history of a CVD
event (aged 40–79 years) or signiﬁcant
CVDrisk(aged55–79yearswithanatom-
ical CVD, albuminuria, left ventricular
hypertrophy, or at least two other CVD
risk factors) to a strategy of intensive gly-
cemic control (target A1C 6.0%) or
standard glycemic control (target A1C
7.0–7.9%). Investigators used multiple
glycemic medications in both arms.
ACCORD participants were on average
62 years of age and had a mean duration
of diabetes of 10 years, with 35% already
treated with insulin at baseline. From a
baseline median A1C of 8.1%, the inten-
sive arm reached a median A1C of 6.4%
within 12 months of randomization,
while the standard group reached a me-
dianA1Cof7.5%.Otherriskfactorswere
treated aggressively and equally in both
groups. The intensive glycemic control
group had more use of insulin in combi-
nation with multiple oral agents, signiﬁ-
cantly more weight gain, and more
episodes of severe hypoglycemia than the
standard group.
In February 2008, the glycemic con-
trol study of ACCORD was halted (em-
bedded blood pressure and lipid studies
are ongoing) on the recommendation of
the study’s data safety monitoring board
due to the ﬁnding of an increased rate of
mortality in the intensive arm compared
with the standard arm (1.41 vs. 1.14%
per year; 257 vs. 203 deaths over a mean
3.5 years of follow-up; hazard ratio [HR]
1.22 [95% CI 1.01–1.46]); there was a
similar increase in cardiovascular deaths.
The primary outcome of ACCORD (MI,
stroke, or cardiovascular death) was re-
duced in the intensive glycemic control
group due to a reduction in nonfatal MI,
although this ﬁnding was not statistically
signiﬁcant when the study was termi-
nated (0.90 [0.78–1.04], P  0.16).
Exploratory analyses of the mortality
ﬁndings of ACCORD (evaluating vari-
ables including weight gain, use of any
speciﬁc drug or drug combination, and
hypoglycemia) were unable to identify an
explanationfortheexcessmortalityinthe
intensive arm (10). In both study arms,
participants with severe hypoglycemia
had higher mortality than those without
severehypoglycemia.However,therewas
a complex interaction between hypogly-
cemia, study arm, and mortality: Among
participants with at least one episode of
severe hypoglycemia, mortality was
higher in those in the standard treatment
arm, while among participants with no
history of severe hypoglycemia, mortality
was higher in those in the intensive treat-
mentarm.Otherprespeciﬁedsubsetanal-
yses showed that participants with no
previous CVD event and those who had a
baseline A1C 8% had a statistically sig-
niﬁcant reduction in the primary CVD
outcome.
The ADVANCE study randomized
11,140 participants at sites in Europe,
Australia/New Zealand, Canada, and Asia
to a strategy of intensive glycemic control
(with primary therapy being the sulfonyl-
ureagliclizideandadditionalmedications
as needed to achieve a target A1C of
6.5%) or to standard therapy (in which
any medication but gliclizide could be
used, with the glycemic target set accord-
ing to “local guidelines”). ADVANCE par-
ticipants (required to be at least 55 years
of age with either known vascular disease
or at least one other vascular risk factor)
wereslightlyolderandofahighCVDrisk
similar to that in ACCORD participants.
However,theyhadanaveragedurationof
diabetes 2 years shorter, lower baseline
A1C(median7.2%),andalmostnouseof
insulin at enrollment. The median A1C
levels achieved in the intensive and stan-
dard arms were 6.3 and 7.0%, respec-
tively, and maximal separation between
the arms took several years to achieve.
Use of other drugs that favorably impact
CVD risk (aspirin, statins, ACE inhibi-
tors)waslowerinADVANCEthaninAC-
CORD or VADT.
The primary outcome of ADVANCE
was a combination of microvascular
events (nephropathy and retinopathy)
and major adverse cardiovascular events
(MI, stroke, and cardiovascular death).
Intensive glycemic control signiﬁcantly
reduced the primary end point (HR 0.90
[95%CI0.82–0.98],P0.01),although
this was due to a signiﬁcant reduction in
the microvascular outcome (0.86 [0.77–
0.97], P  0.01), primarily development
of macroalbuminuria, with no signiﬁcant
reduction in the macrovascular outcome
(0.94 [0.84–1.06], P  0.32). There was
no increase in overall or cardiovascular
mortality in the intensive compared with
the standard glycemic control arms (11).
VADT randomized 1,791 partici-
pants with type 2 diabetes uncontrolled
on insulin or maximal-dose oral agents
(median entry A1C 9.4%) to a strategy
of intensive glycemic control (goal A1C
6.0%) or standard glycemic control,
with a planned A1C separation of at
least 1.5%. Medication treatment algo-
rithms were used to achieve the speci-
ﬁed glycemic goals, with a goal of using
similarmedicationsinbothgroups.Me-
dian A1C levels of 6.9 and 8.5% were
achieved in the intensive and standard
arms, respectively, within the ﬁrst year
of the study. Other CVD risk factors
were treated aggressively and equally in
bothgroups,withthetrialachievingex-
cellentbloodpressurecontrol,highlev-
els of aspirin and statin usage, and a
high degree of smoking cessation (12).
The primary outcome of VADT was a
compositeofCVDevents(MI,stroke,car-
diovascular death, revascularization,
hospitalization for heart failure, and am-
putation for ischemia). During a median
5.6-year follow-up period, the cumula-
tive incidence of the primary outcome
was not signiﬁcantly lower in the inten-
sive arm (HR 0.88 [95% CI 0.74–1.05],
P  0.12). There were more CVD deaths
in the intensive arm than in the standard
arm (38 vs. 29, sudden deaths 11 vs. 4),
butthedifferencewasnotstatisticallysig-
niﬁcant. Post hoc subgroup analyses sug-
gestedthatdurationofdiabetesinteracted
with randomization such that partici-
pants with duration of diabetes less than
about 12 years appeared to have a CVD
beneﬁt of intensive glycemic control,
while those with longer duration of dis-
ease before study entry had a neutral or
even adverse effect of intensive glycemic
control. Other exploratory analyses sug-
gested that severe hypoglycemia within
the past 90 days was a strong predictor of
the primary outcome and of CVD mortal-
ity, with an association of severe hypogly-
cemia with all-cause mortality apparent
only for participants in the standard arm.
An embedded ancillary study within the
main VADT showed that baseline coro-
nary or aortic calcium scores predicted
future CVD events and that intensive gly-
cemic control signiﬁcantly reduced the
primary CVD end point in those with low
baseline coronary artery calcium scores
butnotinthosewithhighbaselinescores.
2. What are potential
explanations for the
increased CVD deaths with
intensive glycemic control
in ACCORD?— Numerous post hoc
analyseshavebeenunabletoproveordis-
prove causes; in fact, the design of the
study renders such “proof” elusive. Ran-
domizationtotheintensivearmwasasso-
ciated with or led to many downstream
Skyler and Associates
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poglycemia; more frequent use of insulin,
thiazolidinediones,otherdrugs,anddrug
combinations; and greater weight gain.
Such factors may be associated statisti-
cally with the higher mortality rate in the
intensive arm but may not be causative. It
is biologically plausible that severe hypo-
glycemiacouldincreasetheriskofcardio-
vascular death in participants with high
underlying CVD risk. This might be fur-
ther confounded by the development of
hypoglycemia unawareness, particularly
in patients with coexisting cardiovascular
autonomic neuropathy (a strong risk fac-
tor for sudden death). Death from a hy-
poglycemic event may be mistakenly
ascribed to coronary artery disease, since
there may not have been a blood glucose
measurement and since there are no ana-
tomical features of hypoglycemia de-
tected postmortem. Other plausible
mechanisms for the increase in mortality
in ACCORD include weight gain, unmea-
sured drug effects or interactions, or the
“intensity” of the ACCORD intervention
(use of multiple oral glucose-lowering
drugs along with multiple doses of insu-
lin, frequent therapy adjustments to push
A1C and self-monitored blood glucose to
very low targets, and an intense effort to
rapidly reduce A1C by 2% in partici-
pants entering the trial with advanced di-
abetes and multiple comorbidities).
Since the ADVANCE trial did not
show any increase in mortality in the in-
tensive glycemic control arm, examining
the differences between ADVANCE and
ACCORD supports additional hypothe-
ses. ADVANCE participants on average
appeared to have earlier or less advanced
diabetes, with shorter duration by 2–3
years and lower A1C at entry despite very
little use of insulin at baseline. A1C was
also lowered, even more gradually, in the
ADVANCE trial, and there was no signif-
icant weight gain with intensive glycemic
therapy. Although severe hypoglycemia
was deﬁned somewhat differently in the
threetrials,itappearsthatthisoccurredin
fewer than 3% of intensively treated
ADVANCE participants for the entire
study duration (median 5 years) com-
pared with 16% of intensively treated
subjects in ACCORD and 21% in VADT.
It is likely that the increase in mortal-
ity in ACCORD was related to the overall
treatmentstrategiesforintensifyingglyce-
mic control in the study population—not
the achieved A1C per se. The ADVANCE
study achieved a median A1C in its inten-
sive arm similar to that in the ACCORD
study, with no increased mortality haz-
ard. Thus, the ACCORD mortality ﬁnd-
ingsdo not imply thatpatientswithtype
2 diabetes who can easily achieve or
maintain low A1C levels with lifestyle
modiﬁcations with or without pharma-
cotherapy are at risk and need to “raise”
their A1C.
3. Why did none of the
trials show a signiﬁcant
beneﬁt of intensive
glycemic control on CVD in
type 2 diabetes—in
contrast to many
epidemiologic studies and
the DCCT follow-up study?—
Althoughrandomizedcontrolledtrialsof-
ten conﬁrm hypotheses grounded in ob-
servational evidence or physiologic
studiesofsurrogateendpoints,thisiscer-
tainly not the ﬁrst time that such trials
have failed to do so. The results of AC-
CORD, ADVANCE, and VADT highlight
the critical need for randomized con-
trolledtrialswithmeaningfulclinicalout-
comes, such as in these trials, to help
answer major clinical questions.
In the three glucose-lowering trials,
other CVD risk factors were treated to a
moderate or high degree, and likely due
to this, all had lower rates of CVD in the
standard arm than originally predicted.
The evidence for CVD prevention by
statin therapy, blood pressure treat-
ment, aspirin therapy in high-risk par-
ticipants, and other interventions is
robust. In type 2 diabetes, where other
CVD risk factors are highly prevalent,
the additive beneﬁts of intensive glyce-
mic control might be difﬁcult to dem-
onstrate except in even larger or longer
trials. It is likely that a real beneﬁt of
glucose lowering on CVD in type 2 dia-
betes,evenifitcouldbeproven,ismod-
est compared with and incremental to
treatment of other CVD risk factors.
Additionally, the three trials com-
pared treatments to A1C levels in the
“ﬂatter” part of the observational
glycemia-CVD risk curves (median A1C
6.4–6.9% in the intensive arms com-
pared with 7.0–8.4% in the standard
arms). Their results should not be extrap-
olated to imply that there would be no
cardiovascular beneﬁt of glucose lower-
ing from very poor control (e.g., A1C
9%) to good control (e.g., A1C 7%).
Allthreetrialswerecarriedoutinpar-
ticipants with established diabetes (mean
duration 8–11 years) and either known
CVD or multiple risk factors, suggesting
the presence of established atherosclero-
sis. Subset analyses of the three trials sug-
gested a signiﬁcant beneﬁt of intensive
glycemic control on CVD in participants
with shorter duration of diabetes, lower
A1C at entry, and/or or absence of
known CVD. The ﬁnding of the DCCT
follow-up study, that intensive glycemic
control initiated in relatively young par-
ticipants free of CVD risk factors was as-
sociated with a 57% reduction in major
CVD outcomes, supports the above hy-
pothesis. Of note, the beneﬁt on CVD in
theDCCT-EDIC(EpidemiologyofDiabe-
tes Interventions and Complications) re-
quired 9 years of follow-up beyond the
end of the DCCT to become statistically
signiﬁcant.
A recent report (13) of 10 years of
follow-upoftheUKPDScohortdescribes,
fortheparticipantsoriginallyrandomized
to intensive glycemic control compared
with those randomized to conventional
glycemiccontrol,long-termreductionsin
MI (15% with sulfonylurea or insulin as
initial pharmacotherapy and 33% with
metformin as initial pharmacotherapy,
both statistically signiﬁcant) and in all-
cause mortality (13 and 27%, respec-
tively,bothstatisticallysigniﬁcant).These
ﬁndings support the hypothesis that gly-
cemiccontrolearlyinthecourseoftype2
diabetes may have CVD beneﬁt. As is the
case with microvascular complications, it
may be that glycemic control plays a
greater role before macrovascular disease
iswelldevelopedandaminimalornorole
when it is advanced.
People with type 1 diabetes, in whom
insulin resistance does not predominate,
tendtohavelowerratesofcoexistingobe-
sity, hypertension, and dyslipidemia than
thosewithtype2diabetesandyetarealso
athighlifetimeriskofCVD(14).Itispos-
sible that CVD is more strongly glycemia
mediated in type 1 diabetes and that in-
tervening on glycemia would ameliorate
CVD to a greater extent in type 1 than in
type 2 diabetes.
Finally, the inability of ACCORD,
ADVANCE, and VADT to demonstrate
signiﬁcant reduction of CVD with inten-
sive glycemic control could also suggest
that current strategies for treating hyper-
glycemia in patients with more advanced
type 2 diabetes may have counter-
balancingconsequencesforCVD(suchas
hypoglycemia, weight gain, or other met-
abolic changes). Results of long-term
CVD outcome trials utilizing speciﬁc an-
tihyperglycemic drugs, intensive lifestyle
therapy (such as the Look AHEAD [Ac-
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atric surgery, or other emerging therapies
may shed light on this issue.
4. What are the
implications of these
ﬁndings for clinical care?—
The beneﬁts of intensive glycemic control
on microvascular and neuropathic com-
plications are well established for both
type 1 and type 2 diabetes. The AD-
VANCE trial has added to that evidence
base by demonstrating a signiﬁcant re-
duction in the risk of new or worsening
albuminuria when median A1C was low-
eredto6.3%comparedwithstandardgly-
cemic control achieving an A1C of 7.0%.
The lack of signiﬁcant reduction in CVD
events with intensive glycemic control in
ACCORD, ADVANCE, and VADT should
not lead clinicians to abandon the general
target of an A1C 7.0% and thereby
discount the beneﬁt of good control on
serious and debilitating microvascular
complications.
The ADA’s Standards of Medical Care
in Diabetes (6) and the AHA and ADA’s
scientiﬁc statement on prevention (15)
advocate controlling nonglycemic risk
factors (through blood pressure control,
lipid lowering with statin therapy, aspirin
therapy, and lifestyle modiﬁcations) as
the primary strategies for reducing the
burden of CVD in people with diabetes.
The lower-than-predicted CVD rates in
ACCORD,ADVANCE,andVADT,aswell
as the recent long-term follow-up of the
Steno-2 multiple risk factor intervention
(16), provide strong conﬁrmation of the
concept that comprehensive care for dia-
betes involves treatment of all vascular
risk factors—not just hyperglycemia.
The evidence for a cardiovascular
beneﬁt of intensive glycemic control re-
mains strongest for those with type 1 di-
abetes. However, subset analyses of
ACCORD, ADVANCE, and VADT sug-
gest the hypothesis that patients with
shorter duration of type 2 diabetes and
without established atherosclerosis might
reapcardiovascularbeneﬁtfromintensive
glycemic control. Conversely, it is possi-
ble that potential risks of intensive glyce-
mic control may outweigh its beneﬁts in
other patients, such as those with a very
long duration of diabetes, known history
ofseverehypoglycemia,advancedathero-
sclerosis, and advanced age/frailty. Cer-
tainly, providers should be vigilant in
preventing severe hypoglycemia in pa-
tients with advanced disease and should
not aggressively attempt to achieve near-
normal A1C levels in patients in whom
such a target cannot be reasonably easily
and safely achieved.
TheevidenceobtainedfromACCORD,
ADVANCE, and VADT does not suggest
the need for major changes in glycemic
controltargetsbut,rather,additionalclar-
iﬁcation of the language that has consis-
tently stressed individualization:
● Microvascular disease: Lowering A1C
tobeloworaround7%hasbeenshown
to reduce microvascular and neuro-
pathic complications of type 1 and type
2 diabetes. Therefore, the A1C goal for
nonpregnant adults in general is 7%.
ADA, A-level recommendation; ACC/
AHA, class I recommendation (level of
evidence A).
● Macrovascular disease: In type 1 and
type 2 diabetes, randomized controlled
trials of intensive versus standard gly-
cemic control have not shown a signif-
icant reduction in CVD outcomes
during the randomized portion of
the trials. However, long-term fol-
low-up of the DCCT and UKPDS co-
horts suggests that treatment to A1C
targetsbeloworaround7%intheyears
soon after the diagnosis of diabetes is
associated with long-term reduction in
risk of macrovascular disease. Until
more evidence becomes available, the
general goal of 7% appears reason-
able. ADA, B-level recommendation;
ACC/AHA, class IIb recommendation
(level of evidence A).
For some patients, individualized glyce-
mic targets other than the above general
goal may be appropriate:
● Subgroup analyses of clinical trials
suchastheDCCTandUKPDSandthe
microvascular evidence from the
ADVANCE trial suggest a small but
incremental beneﬁt in microvascular
outcomes with A1C values closer to
normal. Therefore, for selected indi-
vidual patients, providers might rea-
sonably suggest even lower A1C goals
than the general goal of 7% if this
can be achieved without signiﬁcant
hypoglycemia or other adverse effects
of treatment. Such patients might in-
clude those with short duration of di-
abetes, long life expectancy, and no
signiﬁcant cardiovascular disease.
ADA, B-level recommendation; ACC/
AHA, class IIa recommendation (level
of evidence C).
● Conversely, less stringent A1C goals
than the general goal of 7% may be
appropriate for patients with a history
of severe hypoglycemia, limited life ex-
pectancy, advanced microvascular or
macrovascularcomplications,orexten-
sive comorbid conditions or those with
long-standing diabetes in whom the
general goal is difﬁcult to attain despite
diabetes self-management education,
appropriate glucose monitoring, and
effective doses of multiple glucose-
lowering agents including insulin.
ADA, C-level recommendation; ACC/
AHA, class IIa recommendation (level
of evidence C).
ForprimaryandsecondaryCVDriskreduc-
tion in patients with diabetes, providers
should continue to follow the evidence-
based recommendations for blood pressure
treatment,includinglipid-loweringwithst-
atins, aspirin prophylaxis, smoking cessa-
tion, and healthy lifestyle behaviors
delineatedintheADAStandardsofMedical
Care in Diabetes (6) and the AHA/ADA
guidelines for primary CVD prevention
(15).
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